NCT07531043

An Evaluation of the Efficacy and Safety of FID 123472 Ophthalmic Solution for the Reduction of Ocular Redness

A Multicenter Evaluation of the Efficacy and Safety of FID 123472 Ophthalmic Solution for the Reduction of Ocular Redness

• Status: Not Yet Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 240 (estimated)
• Sponsor: Alcon Research · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy and safety of an investigational ophthalmic solution in adults with ocular redness due to minor eye irritations.

Detailed description

Eligible subjects will be expected to attend a total of 3 in-office study visits over a period of approximately 1 week. Subjects will receive a single dose of the study treatment in each eye on Day 1 (Visit 2). Eye redness will be assessed before and after instillations at prespecified timepoints.

Conditions

• Ocular Hyperemia

Interventions

Type	Name	Description
DRUG	Apraclonidine Ophthalmic Solution, 0.125% Unit Dose Preservative Free	Investigational ophthalmic solution applied topically to the eye in a unit dose preservative free (UDPF) formulation
DRUG	Vehicle	Inactive ingredients of FID 123472 applied topically to the eye as an ophthalmic solution in a unit dose preservative free (UDPF) formulation

Timeline

• Start date: 2026-10-01
• Primary completion: 2027-11-01
• Completion: 2027-11-01
• First posted: 2026-04-15
• Last updated: 2026-04-17

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study